Sign up
Pharma Capital

C4X's latest pre-clinical data burnishes the potential of its addiction drug

Orexin-1 is being developed to target the craving process and therefore is expected to be used across a broad range of substance disorders
smoker in monochrome
The firm's lead drug could help the millions of smokers who relapse each year

C4X Discovery Holdings plc (AIM: C4XD) said it had presented pre-clinical data at a leading industry conference that strengthens the evidence base backing the potential of its anti-addiction drug.

Orexin-1 is being developed to target the craving process and therefore is expected to be used across a broad range of substance disorders.

READ: C4X hails progress as it starts to “see the power” of its Taxonomy3 drug discovery platform

On Saturday (Nov 11) at the Neuroscience 2017 meeting, in Washington DC, delegates were furnished with new efficacy stats generated by the company’s lead compound, C4X_3256.

The latest study assessed nicotine self-administration and cue-induced reinstatement; the latter is where strong cravings are triggered by an object or ritual closely associated with taking an addictive substance.

C4X said the latest information supported the development of C4X_3256 as a therapy across two distinct areas of nicotine abuse: smoking cessation and relapse in smokers.

READ: C4X Discovery Holdings says it is on course to become a self-sustaining drugs discovery 'engine'

"This set of studies strengthens C4XD's pre-clinical data package for our lead Orexin-1 antagonist programme,” added the firm’s chief executive, Clive Dix.

“We strongly believe that the programme presents a compelling commercial case for partnership due to its broad applicability to substance use as well as related disorders, such as anxiety, post-traumatic stress disorder, and impulse control.

“This is supported by the high level of pre-clinical partnering interest received that have enabled us to enter late-stage commercial discussions."

Why Invest In C4X Discovery Holdings plc? Read More Here

Register here to be notified of future C4XD Company articles
View full C4XD profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.